Chen, JinboJinboChenHuang, Chi-PingChi-PingHuangQuan, ChaoChaoQuanZu, XiongbingXiongbingZuOu, ZhenyuZhenyuOuYU CHIEH TSAIMessing, EdwardEdwardMessingYeh, ShuyuanShuyuanYehChang, ChawnshangChawnshangChang2023-07-142023-07-142023-0917594812https://scholars.lib.ntu.edu.tw/handle/123456789/633601Bladder cancer is the ninth most common cancer worldwide with a striking sex-based difference in incidence. Emerging evidence indicates that the androgen receptor (AR) might promote the development, progression and recurrence of bladder cancer, contributing to the observed sex differences. Targeting androgen-AR signalling has promise as potential therapy for bladder cancer and helps to suppress progression of this disease. In addition, the identification of a new membrane AR and AR-regulated non-coding RNAs has important implications for bladder cancer treatment. The success of human clinical trials of targeted-AR therapies will help in the development of improved treatments for patients with bladder cancer.en[SDGs]SDG3journal article10.1038/s41585-023-00761-y370724912-s2.0-85153111834https://api.elsevier.com/content/abstract/scopus_id/85153111834